Advertisement

Topics

Endocyte Company Profile

05:35 EST 10th December 2018 | BioPortfolio

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal healthy cells causing serious side effects. These side effects can be life-threatening which leads to suboptimal dosing. Receptor-targeted therapeutics can be more effective because they can be targeted with lethal precision to high affinity receptors over-expressed by diseased cells. Our initial focus is on a receptor for the vitamin folic acid, which is often over-expressed on cancer cells. By attaching drugs to folic acid, the vitamin acts like a “Trojan Horse” to target and deliver drugs to cancer cells, which could allow higher and more effective doses to be given with reduced side effects. 1988-1996
Researchers in Dr. Philip Low’s laboratory at Purdue University discover a new entry pathway for vitamins into plant cells and demonstrate that proteins can be delivered into plant cells via this pathway if they are first attached to the vitamins (initial discovery published in Plant Physiology).

Researchers in Dr. Low’s laboratory observe that proteins can also be delivered into cultured animal cells by piggybacking the proteins on to vitamins. Discovery of folate-targeting was made by Philip Low and Chris Leamon in 1989 (initial discovery published in Proceedings of National Academy of Sciences).

Research from other labs demonstrates that the uptake pathway for folic acid is primarily present in cancer cells, allowing Endocyte’s future use of folic acid as a Trojan horse to target folate-linked drugs specifically to cancer cells.

Location

3000 Kent AvenueSuite A1-100
West Lafayette
Indiana
47906
United States of America

Contact

Phone: 765.463.7175
Fax: 765.463.9271
Email: information@endocyte.com


News Articles [85 Associated News Articles listed on BioPortfolio]

Novartis to acquire biopharmaceutical firm Endocyte for $2.1bn

As per terms of the deal, Novartis will purchase all outstanding shares of Endocyte common stock by paying $24 per share. Through using drug conjugation technology, Endocyte will The post Novartis to...

Novartis to buy cancer drug firm Endocyte for $2.1bn

Novartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash. The Swiss pharma giant is buying the US-based Endocyte to expand its radiopharmaceuticals business. News of the p...

Novartis Buys US Biopharma Endocyte

Novartis has agreed to buy US biopharma Endocyte, gaining access to radiopharmaceuticals, which the Swiss drugmaker has identified as a key growth driver of its business. Under the terms of the deal, ...

Novartis Acquires Endocyte for $2.1 Billion

Novartis benefits from the acquisition by expanding its radioligand therapy (RLT) platform, while Endocyte and its shareholders will receive a premium price for the deal. The post Novartis Acquires En...

Novartis Buys Endocyte for $2.1B, Making a Second Bet on Radiotherapy

Novartis has agreed to pay $2.1 billion cash to acquire Endocyte, expanding an ongoing effort by the Swiss firm to develop targeted radiation treatments for cancer. Under the agreement, Novartis (NYSE...

Novartis to Pay $2.1 Billion for Acquisition of Cancer Drugmaker Endocyte

Basel, October 18, 2018 – Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted t...

Novartis to pay $2.1B for drugmaker Endocyte

Swiss pharmaceutical company Novartis plans to buy US-based cancer-drug developer Endocyte for $2.1 billion.  -More- 

Novartis to acquire US cancer drug developer Endocyte for $2.1bn

Swiss pharmaceutical firm Novartis has signed a $2.1bn deal to purchase all outstanding shares of US-based biopharmaceutical company Endocyte in...Read More... The post Novartis to acquire US cancer d...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Extension Study of EC145 for Subjects Enrolled in a Previous Study With EC145

This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 and have continuing evidence of cli...

Companies [4 Associated Companies listed on BioPortfolio]

Endocyte Incorporated

Endocyte, Inc is a biotechnology company focused on vitamin based drug targeting and delivery systems. Vitamins are essential components for specific biological cellular functions. Endocyte's mission ...

Endocyte, Inc.

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced propr...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal h...

Merck and Endocyte

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines,...

More Information about "Endocyte" on BioPortfolio

We have published hundreds of Endocyte news stories on BioPortfolio along with dozens of Endocyte Clinical Trials and PubMed Articles about Endocyte for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endocyte Companies in our database. You can also find out about relevant Endocyte Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record